Seagen (SGEN) 17 Jul 192019 Q2 Earnings call transcript

Company Profile

Participants

Peggy Pinkston	VP, IR & Executive Director of Corporate Communications
Clay Siegall	Co-Founder, Chairman, President & CEO
Robin Taylor	Chief Commercial Officer
Todd Simpson	CFO
Roger Dansey	Chief Medical Officer
Kennen MacKay	RBC Capital Markets
Matthew Holt	JPMorgan Chase & Co.
Michael Schmidt	Guggenheim Securities
Andrew Berens	SVB Leerink
Maryana Breitman	Goldman Sachs Group
Gena Wang	Barclays Bank
Tazeen Ahmad	Bank of America Merrill Lynch
Stephen Willey	Stifel, Nicolaus & Company
Shanshan Xu	Berenberg
Andy Hsieh	William Blair & Company
Silvan Tuerkcan	Oppenheimer

Call transcript

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to today's Seattle Genetics Second Quarter 2019 Financial Results Conference Call. Today's conference is being recorded.

For opening remarks, I'd like to turn the call over to Peggy Pinkston, Vice President of Investor Relations. Please go ahead.

Peggy Pinkston

Thank you, operator, and good afternoon, everyone. all Call. to welcome Quarter Genetics' to Conference XXXX like of Seattle you Second I'd today Clay Officer; me Medical - Financial With are and Officer. Robin Officer; Chief Officer; Taylor A Executive Chief Dansey, Commercial Roger Todd Chief Siegall, Simpson, Chief President and in Accompanying website are on call Events section conference slides, which Investors today's available and are supporting our the Presentations page. remarks today, for line we'll questions. the prepared open our following And [Operator Instructions].

statements anticipated revenues, regulatory the to and the including submissions Today's and including sales ADCETRIS regarding such anticipated will future achieve XXXX conference forward-looking regulatory and future milestones, cost and financial others, timing approvals. and of include potential the among future data expenses; and company's clinical operating readouts, or company's those, and performance the XXXX company outlook, events as future to call relating financial

sales, results statements. such Actual these difference difficulty in from developments may materially the process. the cause pharmaceutical that forecasting and differ and or or the regulatory a development those implied projected approval uncertainty associated may revenues Among include expenses with factors and the forward-looking in

risks Exchange uncertainties company's report More periodic the ended quarter in on filed XX-Q XXXX. company's is Securities Risk Factors, and the the about faced included the Genetics by reports the for the with contained Commission, information including under and Seattle caption Form quarterly March XX,

Clay. turn I'll over call Now to the

Clay Siegall

focused our afternoon, the growing into few on past goals company. multiproduct evolution good important months, continuing oncology In and everyone. delivered Peg, brand on a ADCETRIS our Thanks, several flagship and we've

EV-XXX urothelial positive submitted in vedotin, includes FDA portfolio been cancer outcome trial. for on metastatic enfortumab late-stage based Our the to of the has approval which

in breast tisotumab other tucatinib pivotal two trials, in in vedotin HERX-positive cancer. cancer metastatic In cervical addition, we're advancing and metastatic programs

million quarter by $XXX available were ADCETRIS from sales for This begin treatment frontline in the now first lymphoma. with reported peripheral Takeda, record mainly of the Canada, up utilization of increased was our the product an -- ADCETRIS, driven global net T-cell in it There some collaboration is XX quarter, U.S. use is and increased in frontline countries. year. XX% we the was with I'll of Under lymphoma. which Hodgkin in the also important second growth In on lymphoma. comments

In quarter addition, these results that reflect ADCETRIS. had seen with strength we second previously

will provide We on progress call. commercial more detail in later our the

triggered country This in partner a and To under million Outside payment of us Canadian Takeda our milestones in Hodgkin received Europe, key ADCETRIS. frontline milestone Takeda approval expand our $XXX and are Europe approved to including and Japan lymphoma million. key approvals to received May, to countries. Japan. million a the approval the we U.S., of $X.X indication frontline continuing and recently date, total Hodgkin outside lymphoma, in $XX.X In achieved collaboration, for third a related we in we've of

For frontline and year. in to Canada to the plans EMA to other this PTCL, we submitted submit May, Health PTCL Takeda our approval frontline approval authorities and for health application also

submission to urothelial and featured Next ASCO data in briefing. in developing which accelerated for on FDA announced The Astellas. EV BLA results EV-XXX the the with we we're enfortumab were collaboration is an metastatic Today, presentation EV, press the an for based at or from of approval ASCO oral study. in vedotin, cancer selected

will our physician expand positive commercial with is beyond the next community. become potential anticipation if encouraged our drug approved, portfolio marketed preparation tumors. positioned to are rapidly advancing. these the reception malignancies launch into to solid our hematologic EV and, approval, We of data is In by

his urothelial including as remarks. clinical cancer. development as plan first-line recap clinical development metastatic well with and the We in to are program working results the advance EV, closely will during Astellas the Roger EV-XXX expand for

development. in surgical These late-stage We're in HERX-positive and candidates vedotin, breast cancer. also cancer metastatic metastatic advancing two include tisotumab TV, other tucatinib in tumor or solid

called pivotal first this expect half year from tucatinib of data XXXX. pivotal and HERXCLIMB the later the from innovaTV line report to trial top called in We XXX trial the TV

that the polatuzumab FDA want relapsed large that date I GSK stated development, targets a half is This of technology collaborators approved and conducting submission trials BCMA. ADC patients in designations, our CDXXb. year. is Genentech this highlight one planning DLBCL. in lymphoma. approval PDUFA are months regulatory an X additional from in that has several to of including of is technology, diffuse targeting advancing developed Polivy, licensees. Among several vedotin, It Genentech than in B-cell of BTD more GSK first Polivy frontline Lastly, ADC the use by for second was ADC of or with late-stage they other our climbed has ahead the

development spent He's like and Genentech. our this At oncology of skills before drugs introduce Genetics the Seattle strategic more years our planned potential suited from May. XX pipeline our point, in - emerging most including commercial I'd Commercial joined recently Officer, A who EV, driving as are presence, contributed he drugs. as commercial Robin to global launch His at tucatinib. other Chief at several such AstraZeneca, than global the marketing and was Taylor of to to successful well as that, Robin well

has he that pleased team. joined the Robin? are We

Robin Taylor

EV data transformational and demonstrated launch continued team, company later This I'm this to investment the tucatinib and ADCETRIS year. new patients the the commercial pipeline. Clay. for to as time for the at Genetics an exceptional have science the by is focus was on late-stage important indications anticipated planned on the with pivotal innovative for Seattle in of clear organization the the this based I and drawn strong excited tremendously time. Thank joined you, leadership

quarter results. in net Let to were the the of ADCETRIS same Canada increase now XX% the in million our an quarter second turn and quarter, to second me U.S. sales XXXX. in $XXX compared

the first compared the first XXXX, million, of a sales year of first For for to of growth half of half XX% half the ADCETRIS $XXX were XXXX. rate the

X in main We attribute the to drivers. growth QX

uptake driven ECHELON-X that positive ADCETRIS CDXX observed approval XXXX. to data CHP this the compared of showed following including plus a indication the U.S. expressing the strong death This November reduction survival XX% of CHOP. by advantage overall in in of the in risk First, continued we've PTCL is

Second, frontline seen ECHELON-X reflects at reported and Hodgkin lymphoma. growth Stage of to we have trial from ADCETRIS positive IV X-year This in data III reception a continued the PFS ASCO.

April brochures. in The Hodgkin resources update ask there addition, options increase patients online been available In their encourages to the contributed. an to to physicians in may This the have also NCCN has our about in unique downloads growth lymphoma. treatment engagement visitors patient ask-your-doctor of and of all frontline for XXXX with Guidelines

Based to we in growth continued these for we of million QX growth observed but sequential strongest the historically of have our and third, the quarters moderate maintaining And are QX guidance patterns, net the $XXX full range year. more between other historical sales year $XXX of ADCETRIS ADCETRIS on in million. XXXX with

the force we Finally, launch. preparing with fully EV be Seattle I launches the very my drug of training preparations hiring that upon will launch the we're team we are and career, FDA activities Genetics rigor ready vedotin I'm and to at participated is confident of oncology have commercial the been actively for pleased depth launch enfortumab to of date. partner close for the multiple successful to over approval. beginning for Astellas. prepared in ensure we're complete, commercial Having Sales with our that

finance provide to Let Todd me to turn now the update.

Todd Simpson

and us call everyone, Great. the in Thanks, Robin, thanks, this for joining afternoon.

Robin were the Total summarize results outlook revenues our to XXXX. So in year. for for the first This I'll the Growth the ADCETRIS net quarter well frontline quarter in the of quarter year. the expansions financial Hodgkin described. as in the dynamics second Canada other our and U.S. in today, of year-to-date provide second $XXX PTCL the XXXX sales year-to-date primarily for in the included $XXX and second as and $XXX label half in million financial for record and and and X million $XXX lymphoma the updates million reflects million that

XXXX in last quarter the compared million million the $XX revenues were to Royalty quarter in of second $XX of year. second

$XX the first royalty compared million half of year. of last XXXX, in $XX revenues were For the half to first million

We expect the trigger royalty Takeda increase as increasing year grow sales throughout ADCETRIS as and royalties to higher sales rates.

royalty XXXX despite Takeda, royalty of royalty increases while which portion cost Therefore, revenues in the by obligations reminder, lower grew at on of royalty revenues revenues XXXX. included ADCETRIS, Takeda's expired in sales some a in paid rate third-party of decreased. As a

forward, reflect such royalty will ADCs, amounts of Going also revenues earned net collaborator on as sales Polivy.

results However, is this contribute to in did our second not guidance. included not quarter and

notably earned our and This of and amounts most the Takeda and of deals, collaboration second million frontline in included quarter of of were under ADCETRIS milestones million Hodgkin million in by which approval second revenues, quarter XXXX, in million XXXX. with half in portion half first the for $XX the includes of Takeda's the and $XX Genentech's in first Polivy $XX our ADCETRIS earned $XX the approvals lymphoma. recent Collaboration achieved ADC

R&D expenses XXXX. $XXX primarily pipeline TV. $XXX for our half XXXX programs, quarter increases in were EV, second tucatinib of million across million The our the reflect first and the on primarily investment and over late-stage

SG&A $XX of the second quarter. in and results addition second quarter. in a commercial slightly variability These support shares first increases half noncash ended which XXXX. our and is quarter, efforts quarter in first core to results These resulted which $XXX the cash in are expenses million the business. end in causes loss a reflect our to to costs pipeline million was of to of second and These related Immunomedics with were quarter late-stage in the the noncash This frontline our $XX We million this not as as is at ADCETRIS second in higher mark-to-market, million well $XXX financial similar the than indications investment gain in for programs. $XXX the in million investments. --

highlight our Lastly, X updates financial I to want guidance. XXXX to

And submission given we EV a increasing Takeda collaboration the million to the vedotin milestones Genentech on in million. for of First announced to morning, all expenses, SG&A we this organization. and deals, sales under with range proceeded guidance anticipation $XXX $XXX the secondly U.S. revenues our on BLA hiring of enfortumab revenues, recent the are substantially

As are $XXX guidance narrowing this, we expenses million to a million. for to and SG&A of increasing range $XXX result a of

Our other guidance remains unchanged.

the Roger. turn over I'll Now call to

Roger Dansey

Thanks, everyone. afternoon, Todd, and good

of also ASCO positive Best oral in rate. an featured at received or as EV-XXX blinded XX% early urothelial both XX% of pivotal Clay the were the metastatic independent who've results response As including trial PD-X are response session program. rate mentioned, June Among cancer complete subsequent and review, PD-LX part a platinum regimen central and confirmed the inhibitor, the patients was by ASCO the

outcomes. poor which obtained. all XX% response setting, EV-XXX were in with at median across have with single-agent those shows complete meaningful the The is subgroups, Responses observed limited current X.X care of rarely standard with rate activity liver months. a including metastases, context, of particularly chemotherapy, response in clinically For duration approximately was the responses patient

EV events these was a have the profile. and Based seeking results Notably, the I rash accelerated with in safety and results, earlier adverse tolerable experience FDA patient EV. Phase a on Astellas pretreated appetite, with heavily included fatigue, approval manageable neuropathy. the are consistent the decreased BLA treatment-related most common we submitted same The population. peripheral to of alopecia,

As designation Breakthrough Therapy patient we in reminder, have a this population.

multiply unmet in metastatic The wide medical opportunities cancer provides EV of a with needs. patients array remarkable activity of for substantial development EV to monotherapy address urothelial treated

plans Our focused areas. EV key X is development on

platinum-naïve. ongoing metastatic PD-LX X are trial proceed ineligible are is PD-X treatment EV-XXX but of cancer the or of cisplatin patients second to for First, in the and cohort who enrollment urothelial

is continues Second, the well. confirmatory to submission support ongoing which EV-XXX, enroll trial global randomized to intended regulatory

this plus in as EV-XXX are EV And randomized from the a cancer well later trial, and other cancer expressing pembrolizumab muscle metastatic with Nectin-X data planned to such the of setting. bladder the is year. stages report fourth, and/or EV platinum earlier we cohort Third, first-line chemotherapy trial, expect as in precursor the pembrolizumab being invasive as tumors. urothelial combines frontline which ongoing This to trials

as Across on I'll X move on meetings. at these sets. several on numerous well Association Conference Malignant now data reported and the subject International was we important congresses, to as Hematology which presentations ADCETRIS, Lymphoma the ASCO European

difference trial, extended was investigators The by an for of with compared AVD XX% X.X%. the determined the that the ABVD follow-up showed ADCETRIS plus in to in we was PFS First, PFS a ECHELON-X benefits arm, XX.X% X-year maintained.

including in prespecified majority improvements observed was patients the prognostic subgroups, treated and consistent the stage ADCETRIS across among Importantly, PFS of score. regimen disease with

including mediastinal the expression multiple showed including specific expression. patients lymphoma be activity analyses trials, levels data level in for several supports third, the across of of ECHELON-X, primary Second, nivolumab, there all B-cell required non-Hodgkin and lymphoma may abstracts CDXX in of with highlighting in Hodgkin that responses lymphoma. ADCETRIS efficacy. These notion combination And no

Importantly, second-line ADCETRIS for to plus nivolumab was NCCN treatment recently lymphoma. guidelines added Hodgkin

of expansion, patients received in after that retreatment setting One today. previously may now published. who of result trials will including in with label with trial in Hodgkin response, I'll are been prior retreatment ADCETRIS first-line mention who patients the data ADCETRIS X evaluate in which and have progress lymphoma we ADCETRIS setting. Lastly, in additional T-cell relapsed/refractory initiating Encouraging the a

who labeled We older due initiating in indication to ADCETRIS believe patients. This chemotherapy a area and combination comorbidities. patients and for that are are physicians PTCL also either important data for trial generating Hodgkin of is age need. of high unmet lymphoma for a We unfit is an or

keep as We and also and label-enabling plans you expect trials, practice-informing to initiate we'll progress. additional posted our

potentially in which status oral our HERX. a trials. highlight briefly Next, tucatinib I'd kinase targets is tyrosine like that inhibitor are of of tisotumab programs late-stage best-in-class Tucatinib the and both vedotin, registration to

conducting metastatic breast outcome results setting pretreated have of treatments. top this in including of year. the with for with are expect we in continue randomized complete, line standard metastases. called a trial patients enrollment to Patients HERX-positive to endpoint pivotal is primary later heavily PFS the and a report care cancer, brain We HERXCLIMB this poor HERXCLIMB

earlier also combination The metastatic second-line alone evaluating aim endpoint We trial endpoint lines a TDM-X a initiating the breast setting. which randomized primary show this cancer. of to this Data TDM-X Phase support standard trial, trial in PFS of secondary published a cancer to in combination. I combining tucatinib to year breast compared tucatinib ADC, Phase With care this we well-established a -- of II with are of improved is with key OS. outcomes a in HERX-positive HERX from is ensure with

an TV, is are with Tisotumab targeting we tissue Genmab. vedotin, partnership factor developing or ADC that in

with objective standard a data complete, are We and We assessment approval no the is where submission and and, recurrent women metastatic trial single-arm, are pivotal If are line the durability response. the accelerated of cervical trial half II Phase trial is estimate Enrollment following support care poor. The there a first confirmed in outcomes of in cancer conducting under for or mechanism. single-agent endpoint could is primary patients regulatory of the response we FDA top XXXX. importantly, of positive, response. reporting

to Now turn over call I'll the Clay.

Clay Siegall

to XXXX next tucatinib with the the XXXX, of patients that activities the first is the Roger. We've further Thanks, in first-line standard need. trials; We'll accomplished first, FDA label; of of in progress include, many I'm from establish line our our of submission the and much making frontline enfortumab results initial poised ADCETRIS, later goal several the trials second continuing with to third, PTCL and care bringing first report product to top ADCETRIS and as updated with rest and advance new keep and These progress. vedotin the for year. in half second, development EV-XXX year trial additional half and with our in to and drugs in program Astellas, in from trial on collaboration top data the are the our report excited expand EV pivotal of trial in EV the line towards TV ADCETRIS HERXCLIMB frontline we're Hodgkin clinical of work half pipeline. the the lymphoma cervical expand cancer initiate you data on important by pivotal

the At call open the for please Q&A. for this line Operator, point, we'll open questions.

Operator

Markets. our Kennen [Operator Instructions]. with first We'll RBC from take MacKay question Capital

Kennen MacKay

inventory should guidance, X, week there the quite if you'll be your on And sequential could Could price in the with seems or of And price here doable. understand a if growth For big ADCETRIS I guidance hike? not you June understand we within because to just hit you'll be of X also increase the with Is which here? hike that quarter. X us the on reading QX squarely seems could QX. you ask help I just upper end topic, us quarter-over-quarter stocking off, team, help there growth. the I guidance ADCETRIS, maybe was only in into the recent and the it X% in first XX anything given be given congrats here. decision was wondering wondering

Clay Siegall

Thanks, Kennen. Thanks for questions. the

we about really guidance, the growing international, and in and U.S., ADCETRIS, think reiterated annual a It's giving We with a pleased to important brand growing it's which So million we brand. reiterated guidance. we seeing. when what we're that as middle please were quarterly frontline note we're we're and over XXXX. approvals, million, of $XXX in XX% is We're guidance while not getting so giving did we $XXX the

we be And can. to so as as a trying and guidance, accurate we're it's strong

have have data particularly our we X-year a was data important, docs, good and and PFS We and with was range spectacular. EX connection with there, EX

not is but You know OS. strong. typically QX But only that, with PFS with

like our future, out Now hard indicates there. it's full exactly in we that what that displace We're I really at marketplace, that what the entrenched guidance just are we're We And standard going our lot. and It's that. know still we're into hard stay at see would care we're say hard there looking to to and out decades-old get. a feel it. force. the tuned, We to out are of and growing products working continuing to work

teams Our connecting we're well, and really with are doing commercial docs.

there's We centers there really that that We that's but small patients, Kennen, not really question, the vials the we don't any cancer really second have more more centers than it, Your hold no you treat some cancer know because that. really see call stocking, stocking. are that evidence as big they inventory.

get they it don't time, any ADCETRIS. quickly. order deliver of We for evidence we stocking see it, people So real in

where just see so we don't and accumulating sites inventory. good we And about we are, really feel

Todd Simpson

I this add comment. Todd. just one is to Kennen, more want And

in in and only did keep net, but X.X% price We net that business, increase. of come gross which to a because increase of that pretty price the half of mind PHS significant. our particularly our about around discounting is have sales July, about see talked You the the we through share

Kennen MacKay

sales into helpful you've and follow-up just one seems the you sales with the SG&A wondering here. been if more the can changes increase? for making that also QX? important that understand I quite help of for a us EV just pulling really Robin, force context, the Maybe like, environment That's ADCETRIS current Is especially and think on given remember. to quite maybe responsible also It is of Clay bit been ADCETRIS guidance there's And tracking website, is force? hiring we sort going that increased Or saw the the here. in sales the that that for

Clay Siegall

to good thing of a thanks the really salespeople you important for be program sales that last and want both work related some thought First continuity EV it ADCETRIS We all, we on the that. would connection, we're replaced type had that EV to come ADCETRIS with ADCETRIS getting, we're of we force. very go Robin, on the It do looking folks proud and is sales the for of to quarter, so the to people mentioning the more from our about some us have talk are of force. to the and of people EV? you said, and

Robin Taylor

in and, course, would depth that experience group high-performance for over we strong did EV the with sales on lot rules. Seattle got of have you some are Yes. great I force. what and sales a interest oncology come seeing have we say with of few say The what saw in really you almost a I'd folks force as for of those sales we've complete, positions. mentioned, -- backfills fully But interest Genetics. over is hiring a EV We EV ADCETRIS the from the I those No, force, of the is very online

Operator

with Our Cory next question Kasimov is from JPMorgan.

Matthew Holt

on Matthew Cory. for is This

international should wondering policy trying any the So that for be the provide my this question, could in regard I'm implemented. was to quantitative potential commentary qualitative pricing proposal ADCETRIS you first index understand on impact and of or I pricing, if

Clay Siegall

we any closely Matt. paying we frequently. we're literally that provide issues changes believe to be medicines company attention ADCETRIS they're aware pharma an biotech or Ultimately, payers. be continue impact is. like There's them. on certainly Thanks, fully another and that patients track first benefits believe by that daily and class, It's really that meaningful are the Look, We're in will innovative dynamic. drug. of or valuable. and will EV, patients, a and have and valued physicians these drugs drug is first-in-class

what so will we're exactly. And not sure happen watching,

I think it of you're as as we are. sure

Matthew Holt

and Got this the my second expected it. year initial the for And then question on tucatinib data HERXCLIMB. is

Just curious the hazard context you're from space. other meaningful of of terms or in treatments in clinically value what would be PFS ratio all KOLs the available in the what hearing

Clay Siegall

data what's want about about in and Sure. context out later do Roger, you coming there little forward We're HERXCLIMB this with talk really year. bit a the excited world? of to the

Roger Dansey

It's Yes. a good Sure. question.

population. has high So we aspects design been patients a to there's of with some design result patient the particularly capecitabine, high enrolled the outcomes. in positive trial that extremely an added the is to of frequency The unmet that's trial very with it, tucatinib HERXCLIMB and with so unique may a thoughtful population triplet a metastases, a is need trastuzumab versus think on doublet brain

meaningful control need isn't hard that and really on you very make In that. to there comments is Again, delta, map a unmet high. a of what to, terms the I total any the can without seeing think specific it's is very absolutely data

enrolled is and everything as We're where readout course, time. we'll trial at this the relative can a the of of said. go decision, the hoping and think to that that's well. at Clay about excited The we're we get I So end year, But know by point.

Operator

with next our Michael Guggenheim. Schmidt from question take We'll

Michael Schmidt

ADCETRIS example. now, what for quarter. I'm in of much was comparable terms increased rates just in see sounds do treatment if What market driven number I -- and the had again at have are those on was sounds you you the me different a wondering by like frontline And do market in use of and ADCETRIS right the well. you this It correct wrong, if for PTCL, bit sales but me moment? quarter about question growth Congrats could little good it from of as in I PTCL on dynamics a TCL? sales subtypes the share a in more comment like

Clay Siegall

you Michael. for Thank your questions,

of first which that attributed to track remarks, we as prepared this, in EX. all, in growth as the we in both in the So regimen, PTCL is growth, we EX was as as think our said revenue well the

Now as in not report to subtypes. in you report not are can being far we're subtypes that to what we all the EX, the as the going We different used tell they can that. we're about going find, specifics but

is market around We market don't was specific and that a bigger was for the almost say we report we in share to share. would it regimen What because that a also decades. specifically number were CHOP displacing, this can get PTCL, X.X we of bigger that that predicted take quarters

that So entrenched easy displace this to it's is not -- therapies. these

good the the PFS data EX news we with Now OS regimen data. had but is not only

improved year, more." doing showing us you're XX treat data lymphoma. of and data, for frontline time. see headwind the months only instance, it "Look, some for we as lymphoma, there, this we now know, some the know got We actually let's how EX, switch with So and in of Hodgkin of frontline well, And that have said, then regimen follow-up. duration EX a so lot shown early to limited the docs a We you past. of for decades little that's and had like adopters, We'd I've and I to to we experienced Hodgkin now X. data had been follow-up

you the But good years definition and the or in So a patients we disease hopefully, within a calling these Hodgkin these X now what at look cure will rate for likely cure you we yet can increase be of look can't And it really are if call that. and in lot these XX long, at go once months, important PFS, while not-too-distant better could survival, lymphoma. can you that out old-fashioned just you start of PFS, PFS. X.X% at future, oncologists, we is cures, past it that's now long-term are a look and get because

that lot And that first to we a attentions. of from PFS, doctors' data with the approval caught think I X-year data when going the produced out we came XX-month that got

And that regimen yet so in and by more not they looked Hodgkin don't have in we OS, it, yet. of at lymphoma, which because frontline contemplated they this, comforted EX, the to saw were have they was EX

the It nearly wrong. of was as PTCL, a with good So in EX, wasn't EX just it takes the standard care there while. With regimen. as nothing was Hodgkin

understand more I data, are improved to data a little I that too. saying. bit our So think so really big I understand age wanted and with a that's of they what the aging doctors see deal,

Michael Schmidt

the Okay. Then I count I about of ferocad might regarding that but obviously, we the in potential had just solid a when pipeline indications, know initial learn question tisotumab was agent vedotin. I wondering other tumors.

Clay Siegall

at with on a generally of looking Yes, TV? what we're definitely can little looking at Roger, we're touch bit cervical cancer.

Roger Dansey

Sure.

program cancer, in on. in a trial other data you So have going cervical with as hopefully in early efforts The readouts pivotal evaluate XXXX. -- but or to is we configured the mentioned, --

and is has express at that's So looking it an tissue we in at fact have a basket role, moment. which a trial factor potentially the where ongoing TV tumors trial, that

But we read that. present data haven't when yet. We obviously, out we'll do,

asset on have going an specifically We ovarian in also cancer.

of trials TV we diseases. for So of have exploring number a cancer other the in different outside cervical potential

Clay Siegall

to we Genmab trying would I what TV. often add actively about partner And speak with our maximize also is

and excited so So that just product working you about the it. on know, hard we're

Roger Dansey

well. trial one combination and And with of have as fact add in pembrolizumab beginnings TV the to is maybe do we piece

running. that's So and up

Operator

our Berens question Leerink. from We'll Andrew take with next SVB

Andrew Berens

a I prepared quarter, said had on as that different also this Congrats off the given two I we you subgroups, but you is know comments. wouldn't think guys. questions, or the opportunity talk And one ADCETRIS new PTCL a on get should prevalent there about a seeing? when they Or patients multiple are going since driving you're a therapy that Is of relapse disease? what is more opportunity? possibility through to of it's patients it prevalent lines are disease really

Clay Siegall

patients. So so about for data what the on on we're incident at, there that's patients, incident diagnosed out -- look, looking we're PTCL, and talking newly

a Kaplan-Meier some diagnosed especially data our of patients patients so we have PFS clinical to on but data on I clearly look of bigger have be and in is therapy and because the the a and you'd not treat a CTCL. data relapse doctors lot you CHP is really before benefited. patients really and working to approval OS that's on we ALCL into can focused don't set hard-pressed look and we ADCETRIS jumping to doctors newly at should in really newly whitespace patients, curves the between one really and because on So are positive labels, mean different and But prevalent. positive. this still that get Kaplan-Meier commercial And they diagnosed team This our with just find in that trials. feel be at I other, curves

Andrew Berens

then with docs and I have of some one kind the the community if some heard patient fears And of done the wondering real from concern that of we've of heard could was concerns waylay to practices. if those what you clinicians? financial be guys that. efforts private for is things so, of some buying docs is billing of a Okay. the the and And

Clay Siegall

to much at say. heard about really haven't have I We all, it

think what pretty PTCL, as is We we there's time heard and with far much in quarter-to-quarter growing physicians rate market -- basis is have We issues which think some in to think it's PTCL. track we on that entrenched at, really as we As reimbursement a our on growth previously we're predicted. take thought this be would there. not for the getting therapy, I out space you're and to regimen in grow looking going the that a share entrench what EX was it

issue. don't as view this said, So buying thing, billing an you and I what

Andrew Berens

limited wasn't to really these about where comments I I and It Hodgkin's think, talking lymphoma EX. originated. is, ADCETRIS was

Clay Siegall

just say know in this. we're don't to Todd, are have don't it I way commercial are, certainly this a we with I you comment? the you have team, aren't I'll so hearing but think explore comes. this the seeing I information where

Todd Simpson

in order is can to say, other just the an a model, efficient it where Well, tomorrow. we site today going I incredibly was drug they'll and keep to thing mind have have

up. a or because shipping. and it weeks for going ADCETRIS buy literally that to and to of need your to fear weeks it's concern show drug this take isn't there and We're hold overnight weeks a So

Operator

We'll from Richter take next Goldman with our Salveen question Sachs.

Maryana Breitman

have Salveen. on wondering, This prescriber And the that metastatic NCCN for we opportunity, patients to tucatinib wondering Hodgkin updates Breitman that due in about how thinking market. updated were We also you were any a to is especially opportunity how couple. do lymphoma, in about guidelines? changes thinking we you're had One, breast with brain activity going cancer, with Maryana color into about metastases, for you're

Clay Siegall

that asked, impact certainly really that or two Thank we what it's questions. for NCCN, that with impact the like that will that that response it's think the to at new you not but we you NCCN that that we thing know have -- doctors, wording the PFS be the Concerning hard the at that what we think we look data that from was. the could We think think tell is X-year and we they because showed ASCO valuable closely. we most

the it with life, it, connects and thing Pathways sales -- that that's seeing. we're doctors EX are own also prescribe those data really to But way all, doctors is patient, its improved that regimen that's slowly. of the pathways how respond benefit give evolve we and and that. that's really at aged what that the think most takes the very don't meet not data for to are and things this and the really part often increased we're With and important NCCN, how

with the to get is that the But goal to pathway. about the drug drug really potent a out validated of so clearly Tucatinib think It's a HERX of them, could and are toxicity that Now first with the raise some very bar we be cause patients HERX -- and There TKIs. it's few have TKIs with a that you a but helping next best-in-class into level the doesn't other and that asked would there. EGF is you opportunity. something drug. a that all receptor tucatinib that our one buy of is not

the benefit trial, to -- We're of population, for As it's far event-driven do as it's trial. the us a the talking on early specific still working little our doing about an and in that. size pivotal

of it really then opportunity. what in what the think just to I the plenty time happens data guided to And the And let's specific talk data. on to there's data. data later this have depends come see And the We future out. for -- the with about year

The then patients importantly put brain metastases. includes And together. is primary endpoint endpoint all the secondary the

to works this a we of most later is then, this really question. So this unique including year. on are it data. the this on we'll data what until looking the another start sets future this will the in trial patients, a design one or set And off that brain excited addressing think Then whether at different couple result works patients, of hold on depend But could on all with met and opportunity adequately that not-too-distant question hopefully your will patients. I address for from

Operator

question take Barclays. from our Gena We'll next Wang with

Gena Wang

tucatinib, -- the the related if of I enroll? designs of also And percentage event you designed trial the Wondering to can Also will a us with XX% and rate met regarding another PFS, PFS maybe ask. patients is question brain you if do a improvement. follow-up plan remind patient, detect what the to

Clay Siegall

Okay.

I points So X got there. your

-- the have need. enrolled, this has, also that roughly that event half the because And of and that's said unmet we trial. So reporting. amount that's something all of major be and is uniqueness the the a it not patients this are for had we detect have know that's to the We one PFS internal are really and measurable XX% keep The have I We're is we we addressing medical confidential. enroll, planning makes true we'd not mets. that information, improvement reported, that something range brain pre-existing to a patients

Gena Wang

quick revenue. regarding one I follow-up have ADCETRIS' Great. quarter And

majority say growth growth So out from frontline PTCL should -- that driven Is be And you PTCL? PTCL. mentioned it mainly to driven to revenue? expect would close the frontline fair the we the million is by million future $XX by growth quarter-over-quarter the $XX of

Clay Siegall

the we're our that but breaking Hodgkin do apart. PTCL in We really said pleased at growth in prepared think apart frontline did not look breaking with plan frontline lymphoma. nor I we remarks on we growth that also have

continue almost a to increased was market Maybe later was looking think year I we like for in late to PTCL, getting it that approved and are than Hodgkin see which XXXX we lymphoma. early goes penetration, XXXX. in that forward,

we're than is But than little at out both because growth a we're this a what pleased slower frontline has year longer there out a maybe lymphoma little it's less just are been but so growing, rate longer, a frontline So with and probably there. Hodgkin PTCL. -- hearing docs out there point its really and a little little from

know had I on on And It's we really questions to a hard guidance of this. guidance. bunch give

in we with uncharted And And Hodgkin, to out in do the up patients. tuned say data what rallying are is have is trying by on appropriate. there when this. the great. we would frontline you to is PTCL. stay are best The can territory provide can frontline great. And aged this, Doctors and we data I and we're data it's that whatever follow We we'll

Operator

Bank take America. We'll from our of Ahmad with next Tazeen question

Tazeen Ahmad

that force salespeople at And a for reads And meaningful? on should especially sense for guys to to in better expect wanted talked rates? on the need Todd is a level you clinically once? about consider do you the data plan what of have the safety approved you'll sales force get that EV vis-à-vis profile of U.S.? diarrhea I top do efficacy guess, it than the hiring just all And I would of you you sales for How anticipate treatments Clay, you out, currently show kind data big as important What of secondly to we how then at hired. tucatinib, a had line? be

Clay Siegall

questions. those So are two different

over of thoughts to to I'd start sales our kind for and Let's talking like explain EV, Robin? force Robin here. the about to turn it

Robin Taylor

Clay. Thanks, Sure.

So really to size the number to with health field. care we've have to in the broad equal bladder ensure practitioners have, who Astellas a cancer. closely an we metastatic force Astellas, We'll treat sales reach that of worked with reps

that's We with Astellas but stand, roles the here. we is existing will mass activities dedicated for really of also EV have equal an which commercial some sort will such as as our brand-specific where And marketing such we utilize infrastructure partnership team. distribution, market

Clay Siegall

to perform registration. the acquired I'll exciting and Cascadian to EGF repeat studies. talking order and drug tucatinib standpoint didn't that, largely single-arm get on is question single-arm studies. for to the And a is second about and safety us in an this efficacy randomized saw the drug bind from really it a And drug a study efficacy the exciting profile. reason because that we a from get onus receptor, So in safety we to really a standpoint is in on sure

what So Rog, are? -- give we can some of about to where context talk

Roger Dansey

Sure.

So as enrolled. you know, HERXCLIMB is fully

historical the control is need substantial some with population this a a can of points, with reiterate precedent define actually of to that patients we Just really metastases. proportion brain the There what the unmet potential high inhibition and for EGFR. is Based its potential are the a its would addition, Those highly its selective efficacy of best-in-class on arm be. molecule. profile That its no lack its both tolerability. is safety key and characteristics tucatinib, of to of HERX

single-arm really make really tucatinib it's we've proceeded data, that's until obviously including look start the we is another very why been TDM-X, to will -- trial. can't the Clay what data encouraging, potential said, trials and with So with like. see But generated as the about we are statements treatments III which any Phase

Clay Siegall

can What is I a out can look terms you've data from of it's lot this add at always in type other that months. say, when Tazeen, sets measured seen And PFS I population, one of you trials. in thing come of

says me loudly, So that, it tell from that work, of my I cancer doing the need. thing in decades to first I you unmet medical see could whenever

measured they drug walk a drug and away patients They cured." just in where It's where So months. something. -- don't patients, We're we're in area it X I'm saying, a there's is. these need Y. for of or get drug "Yay, an lot respond not talking

have really area to big we a So important go into.

patients out literally And not have anything brain metastasis, get, really half when there. the which you there's

good job So it's patients really help prognosis, do and to we're grim this trying and drug. and a work on a

data, it's year. sometime soon So coming this

excited. We incredibly are

But right the they this we trials. data. and challenge, this randomized yet And in forward and we're reporting FDA to I'll that all the And to They it. the single-arm we're with wants want really rightly just thought randomized were have drug. drugs. other data do setting outstanding, up to remind was and not you, we see data all the We from loved looking

Tazeen Ahmad

months improvement Okay. And rates? about safety, any that's differentiator this population? medical improvement? how that you in are that when important you you on up, high wrap think and then you just is unmet is this as a area, need it, an in Do said, have diarrhea thinking good the is to PFS Clay, Or a

Clay Siegall

data pivotal early I data dramatic not a obviously shows early this on And reported because would go data any in toxicity. difference GI back this trial. we've from to drug our

EGF inhibitors first receptor. I'll to were inhibit they bind two you EGF just them don't remind bind believe bind to tyrosine but don't not and You the that the that kinase EGF both HERX to receptor. tyrosine both And both HERX that were receptor. approved kinase I bind screened of to

not HERX with something the for screened I activity. TKI it to HERX only EGF for think TKI potent screened was bind Whereas but specifically they were receptor. getting didn't tucatinib screened that

So drug. about this what's is unique this

that it's that from treated patients -- single-arm trials, out of the are comparison to dramatically the safety literally in look at hundreds profile there, were others different. it's if for standpoint pretty And a you of

know you -- didn't I trial that? Roger, you And just want you we Do anything I about have out? it competitor, do safety So how a think -- is would randomized that active how versus would feel add confident very come in anything? profile. to We're to

Roger Dansey

No, I do.

think a blinded you're only be which can placebo-controlled tell case HERXCLIMB agent. -- just placebo And trials the active or around is unable safety I'll the remind a general, drug just on, So you're to that I placebo-controlled point you as in done if trial. is in profile, a

which secondly, remember. in is And So that's chronic breast important tolerability is point disease a like cancer, a to an key. disease,

long, into can't is just a for taking it you're twice and issue. it's not take you too can as a It If safety feed day efficacy it potentially drug well. a

So X I points are of some think consideration. those really

Operator

our Stifel. question with Stephen from Willey next take We'll

Stephen Willey

good quarter. Congrats on a really

on PTCL on question tucatinib. quick a one Just and

guess step demonstrating ADCETRIS curious the utilization for recent change potentially CDXX may extent And represent either what the that? to how expression reimbursement just is that or rate-limiting does not expression a from benefit agnostic or right ADCETRIS CDXX screening for So PTCL, the to data just may perspective. in I now

Clay Siegall

the able patients that So the high had or certainly, without through they at or low able to from that said whether were CDXX ASCO histology being you it. be responses docs see presentation even even saw CDXX -- CDXX to

when all you historically, them with you -- can Now histology. we've look looked at patients, these and

noise. a has big Histology area very background gray

get down to whether know you of or negative. when So lower it's positive levels CDXX, to it's impossible

same find that negative and can when negative. at and lymphoma the T-cell at say, to it doesn't amounts find just mean but you can You molecularly. and you up within -- And a you And a we hard-pressed are different CDXX look patient. that's histology also, kind CDXX negative, nodules, down. lymphoma is you an And at when of of different that's look it and goes look CDXX activation antigen, -- molecularly even

showed up their a patients is at in go respond down. where and complicated would doctors all fact, what very presentation all it CDXX So because is can is prediction be the the And there ASCO. scenario exactly in that and that in

benefit good think and patients. have I this and and the I subtypes different a there case to all know, we that everything use really it could on of So think data in we should utility based our it doctors

And hurts. a So I second certainly don't you tucatinib? question on think had that

Stephen Willey

then. the which a by do think? Yes, narrative just could if that you I mechanism of requirement expression were you that the remove there on uptake, label, quick from change that would CDXX follow-up a guess,

Clay Siegall

there -- Hodgkin if there positive. And I it's not says requirement it's at in T-cell CDXX all. just in is mean lymphoma, Our on lymphoma,

mean could trace not be like it's of a -- So it positive. I and it be

quite So an all, it at find we as impediment don't frankly.

Stephen Willey

TDM-X on second in tucatinib, clarification study Okay. about I And talking combination then here line. just another in you're with the for that know

contingent initiation Just if clarify want is of trial upon that the data. HERXCLIMB to

Clay Siegall

that? you comment on to do Roger, want

Roger Dansey

think in and properties the direction. pathway, it's the data This to supports right which Phase It's not. combination. -- proceed right it's time, validated believe time all No, I we we is And described. tucatinib, again that it's a we've the the the we've generated the

Operator

our We'll from Markets. question next with Berenberg take Xu Capital Shanshan

Shanshan Xu

the question follow should positive, up beyond one have readout tucatinib? is have for Roger. for indications upcoming And I of cancer If HERXCLIMB about for how EV. breast think we one I expanding

Roger Dansey

Thanks Sure. the for question.

we all we by So looking incorporated applications. us as being into have tucatinib know, at neoadjuvant

HERXCLIMB population. in see metastatic now into multiple-treated cancer. moving We're You breast the second-line

this in We with data Herceptin later data combining have a have year. which that investigator-initiated an colorectal together has population. third-line-plus cancer MOUNTAINEER, to called We out trial hope tucatinib

potential I will in a HERX if its where than anywhere turns best-in-class, TKI again, can tumor expressing tucatinib to realizes out have to a we be a potential that want go. role the is it think,

that includes that CRC. of as expressing cancer. be breast potentially are So cancers stages It are that gastric other well. of other HERX interest could includes cancer, There

think as I if fully here we out So will have we flesh we molecule real the development a as appropriately, can. plan

Clay Siegall

out our well tablet it's I we that's way HERX really tolerated good with think and the it a proposition works. for breast cancer a could oncologist a to if think data clients turns have

be outside of drug different cancer and I and it. think will of important would in and will -- use be -- -- of therapy, a and would get breast a in many line be in lot this really

go question? So you had an ahead, EV

Shanshan Xu

up Yes, on follow I your absolutely EV. agree with commentary tucatinib. on One

of months to of OS impressive frontline a than very in trial. is carcinoma. third-line a In care standard witnessed X which EV-XXX median we the only So shorter data X is the urothelial EV-XXX,

move achieve EV it pivotal enrollment. ASCO, trial carcinoma. that the is of So we into its In interest almost CALGB-XXXXX the I past everyone's believe saw in X took actually this full years frontline urothelial the to to

urothelial So are Clay, Roger EV? what for frontline and enrollment accelerate to potential for trial drivers carcinoma

Clay Siegall

make commentary a before I on of getting First want your all, question to EV. to

analyst We question it of be your of will models. July, most it's middle year, months in in We faster. EV. this which or submitted July. many to And from comment and the submitted from single have is our busted if ahead analyst we the sometime not speed this so much with it submitted had and We had guided a any back that we submitted where this you

sometime models. of of fall middle most the you in think in I had your

getting notice I translate the I analysts think would market product this So will that, into faster. the which on to like

And it's that an product important are screaming doctors for.

So patients' difference and thing. night important, this on just trying a It's lives, patient make thing. a with like Street Astellas, parcel a we're getting to to noon is and morning, part submission This it's because this a into in isn't okay? we, together and worked Wall

how And so worked everyone want this. notice fast we I on to

a excited different to and Secondly, about of there's approaches. Roger, we are EV you of frontline, want the give in lot potential that? do to context

Roger Dansey

Sure.

our if So can Those inhibitor, and of say the a must metastatic high you we're you. choices plus/minus look PD-X chemotherapy. a I backbone, understand what potential trial, still EV with This choices unmet XXX is urothelial the can is that It's cancer back the with I frontline facing. into you are types are. EV agree need.

support presented trials chemotherapy data I the And just be think times there That's question that of so would CALGB slow. that question, are hope in, with changed interest EV would anything lot we was that. now. thoughtful, other would possibly if whereas chemotherapy, immunotherapies drive I an interesting cancer with the moving on an we that a trial of that than excitement was ahead, to in answer. the of where the trial all around quicker enrollment. really a why that past up bladder way combination once lot very has there's come because Bladder personally have focused will not not like come exciting a versus doctors drugs, the cancer acceptable considerate, of we design, and

Operator

question next Hsieh William Andy Blair. our with take We'll from

Andy Hsieh

Congratulations point see to nice team. that the inflection It's Seattle to Genetics commercially.

for have two One Roger. probably I So questions. is

and oral pertaining other and if is So tucatinib, versus potency specificity TKIs? us potential differentiator to could remind you the that HERX mutants, of specifically

Roger Dansey

the for question, Thanks Andy.

mutant are We population. in the interested

forward very in We neratinib selectivity it, so to is potency. need to haven't close. are we terms studied that's very its potentially HERX and something move of on. that Tucatinib They similar

back which with good is sort the where we're coming neratinib. mutants, ability there's interested. Again, is other the any tucatinib, signal available, for to as we anywhere need potential So tucatinib of currently inhibit a HERX find. role most the to Again, potent as inhibitor target the

future So that's our efforts. for

Clay Siegall

on other one that see is believe Andy, this patient, when these can't you they're based better. the with pressure of HERX like about with tumor for in on the pressure is really the in instance, and things And TKIs you the -- keep if HERX on keep you patient And that's data TKIs agents. we does Herceptin, a what toxic tumor.

enable discontinue have get patient to You not therapy. to and the

Roger when also saw just relates a that as this. we said saw on pressure the substantive So and this of efficacy. and of on could it's it time, lot what that's not before, really a -- tumor keep the change the And what's diligence safety for TKI raise did a important. paradigm it's bar to that's not we a We to allow issue, for period and

Andy Hsieh

a Just this follow-up, and as to EV. pertains

sort a when time the you duration take Phase of go III response any of to Phase Ib from of penalty. rate pivotal most studies, So early you PFS

of consistency pooled factors these impressive top any XXX have just curious, kind line across to the you and -- identified contribute early-stage the the results? Just analysis that

Clay Siegall

to even been overexcited don't too I that. and get and Seattle I reviews team emphasized with data blinded things but Phase that we will we Roger Roger had certainly you is more at tell third-party Genetics case to like unless joining, the the clinical about do prior want

confirmed So want at responses. just responses. to we at We not look look

interested bigger you rate and not been later, that, lives for data this the see much and smaller needs we've lot they're out in that high I response of just already because and as less points little because or of as it's with responses, Genetics' been responses. Seattle more says point making a things. history, in we all data, Phase in We're companies and hype see And confirmed will on substantive pretty some medical Gen's put times then chance unmet interested at stared duration, that actually I where they at you Seattle that's a drugs. much are. getting -- and unconfirmed and when is have fastidious patients weren't improvements in study So see these a it all bit these at, a And repeat

it want there, the the data way, addition? pivotal that's what our out with I closely Roger, matching to do we So the real pretty and to the early-stage rigor. we data same same contributes because any think

Roger Dansey

Two other comments.

when again drugs good they really and work again. That's of work, and they firstly, really So work, this. one really certainly part

talking sizes patients. plus. The or other not the XXX is mind just are XX We're bear patients in XX sample

than around in yourself where those small intervals very variability is so misled. potentially a contrast much sample you the size And can a smaller get

it's great that reproducible. So the data is

described that You're had Phase right. EV, with that experiences Many that to Clay that's and times, obviously the anyone over something see. degrade certainly, But time, I not we experience. not likes have

it bode And for so drug. does the future of the well

Andy Hsieh

Super helpful context.

Operator

Tuerkcan Oppenheimer. question Silvan final from our with take We'll

Silvan Tuerkcan

leaps at quickly color quarter on with centers in the out the of you what roll payers you and how that strategy your prelaunch give activities us a target? sales terms force, this as Could can maybe out of you you have? And also the in terms on please for bit submission. to EV is there any outside such Congrats little more of interactions

Clay Siegall

of mean it's you the large in we deal. across in this First the is question. on for areas. will our I lots -- activities thank of and very prelaunch a all, mean real are this the for effort of drug's amount I board putting EV, I different

not in light sure. want put context? for to share you We're a full launch. we're No in going EV for So in going the soft, in for soft launch. Robin, this

Robin Taylor

payer also the the of Yes, that you of organization, force be And Like commercial. the it's be approval. training of prepared certainly, not preparing launch, rest going new and at as materials, sales terms any to just in product that's the understanding for doing It's you're to you outside say, also the everything preparing Clay. environment. need

market. side, medical medical course, been the And in strategy preparing going terms more our of will product brand months how actually of organization be the affairs the this on year prepared. So thinking position and we've even in to than a already, for we're through

and coming is very into And is the what launches, team was saw Seattle I in so I Genetics experience is that what that I prepared. think said of all oncology elements impressed. these -- my really I

Silvan Tuerkcan

expect do Great. And [ph]? you an AdCom

Clay Siegall

we positively We Roger, therapy don't thinking actually. whether But [ph] or pretty our But not have not. decision. and can -- this drug. on do designation, never we're make this, to I comment AdCom that want breakthrough a there's an It's handicap about addition? I think any

Roger Dansey

agree. Agree. I

Silvan Tuerkcan

mature activity for Maybe be that What metastases data just any brain do will trials? may the on PFS in and metastases seen will have And important, enough date the quickly -- tucatinib, this I Will you're point? time very studying line think top at great you we be entire trial? line data it to that top it. brain to be it's in earlier at that put same of

Clay Siegall

considerably surprised a setting, we been brain data. with I looking better, in Yes, metastasis, would've historic do study. mets studies. a was the other patients we prove populations data But nice were have was to in we of not looking trial. brain on to relatively a you out us on expected to at it, mets did seeing single-arm single-arm in That to was randomized stuck based but early well in brain as in say, the than with but really better, in see met drugs randomized reviewed -- has that and pleased, trials, at were surprised you it data was there -- have brain data should with trial in this we something at So in that not that do randomized the you this,

any Roger, that's on comments So that. other this?

Roger Dansey

agree. I

For in the clearly we've metastasis. active generated, tucatinib data brain is that

no I think doubt. there's

what a what And that think obtained release matter line, it's would we'll combination release. we'll the top be into so we're about in active specifics don't any I With in of data that testing. regard get to how

Clay Siegall

that's say to what premature Yes, exactly we'll release.

Antonio cancer everything mean conferences the doctors premier But breast but premier at the conference. to cancer, peer-reviewed is but we Now retaining Or presented conference. way, appropriate it our it to being possibly an work cancer goal conference. meeting, it's this would while release be breast large ASCO that be is the at other to cancers. ESMO I at to is normally can and ability is breast and San as didn't specializes which clearly It evolved cancer use breast such the for Antonio conference in present now. San the also that some And

Operator

Ladies I speakers for additional closing your like this question-and-answer back would session. any turn to and remarks. the or concludes conference gentlemen, today's to

Clay Siegall

operator, you, joining afternoon. Thank good for Have this and a Okay. night. thanks, us everybody

Operator

concludes and We today's conference. participation. Ladies this gentlemen, your appreciate

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.